Akebia Q3 revenue falls to $36.9 million as net loss reaches $14.4 million
Akebia Therapeutics reported third-quarter 2026 results on November 5, 2026. Total revenues fell to $36.9 million from $58.8 million a year earlier, and the company posted a net loss of $14.4 million compared with net income of $0.5 million, mainly due to lower Auryxia sales. Vafseo patient count rose to about 11,500, but Vafseo revenue was pressured by a customer inventory reduction.
Key points
- Auryxia net product revenues were $20.0 million, down from $42.5 million in Q3 2025; the company expects Auryxia revenues to decline in 2026.
- Vafseo net product revenues were $14.8 million, compared with $14.3 million in Q3 2025.
- Net loss per share was $0.05, compared with $0.00 per share in net income a year earlier; results include a $1.3 million restructuring charge.
- Cash and cash equivalents were $159.3 million at September 30, 2026, and the company plans to refinance its senior secured term loan facility.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.